Filgotinib for Crohn's disease-expanding treatment options

Affiliations

¹ Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA. Electronic address: aananthakrishnan@mgh.harvard.edu.

Comment

Ashwin N Ananthakrishnan. Lancet. 2017.

. 2017 Jan 21;389(10066):228-229.

doi: 10.1016/S0140-6736(16)32538-7. Epub 2016 Dec 15.

¹ Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA. Electronic address: aananthakrishnan@mgh.harvard.edu.

No abstract available

Comment on

Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.
Vermeire S, Schreiber S, Petryka R, Kuehbacher T, Hebuterne X, Roblin X, Klopocka M, Goldis A, Wisniewska-Jarosinska M, Baranovsky A, Sike R, Stoyanova K, Tasset C, Van der Aa A, Harrison P. Vermeire S, et al. Lancet. 2017 Jan 21;389(10066):266-275. doi: 10.1016/S0140-6736(16)32537-5. Epub 2016 Dec 15. Lancet. 2017. PMID: 27988142 Clinical Trial.